Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2004 - Systemic and metabolic effects from OSA Year: 2004
Fibrinogen level in patients with severe obstructive sleep apnoea syndrome (OSAS). Effect of n-CPAP therapy Source: Eur Respir J 2001; 18: Suppl. 33, 216s Year: 2001
Angio-inhibitory activity and decreased leptin level in sera from obstructive sleep apnea syndrome (OSAS) patients Source: Eur Respir J 2001; 18: Suppl. 33, 334s Year: 2001
Investigation on serum adiponectin levels in patients with obstructive sleep apnea hypopnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 445s Year: 2004
Plasma orexin-A levels in patients with obstructive sleep apnea syndrome Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005
Comparison of plasma NT-proBNP level in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008
Serum leptin levels in obese patients with severe obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
The effect of theophylline and CPAP on cytokine release in patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2006; 28: Suppl. 50, 216s Year: 2006
Elevated c-reactive protein in patients with obstructive sleep apnea hypopnea syndrome (OSAH) Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007
Serum resistin level in pediatric obstructive sleep apnea Source: Annual Congress 2008 - Paediatric respiratory epidemiology I: primary ciliary dyskinesia, sleep-disordered breathing, exercise-induced symptoms and rare diseases Year: 2008
PAI-uPA system in patients with obstructive sleep apnea syndrome (OSAS) in CPAP treatment Source: Annual Congress 2012 - Cardiovascular disease and sleep-disordered breathing Year: 2012
Serum leptin levels in obstructive sleep apnoea patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
Effects of CPAP treatment on physical fitness in patients with obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2003; 22: Suppl. 45, 97s Year: 2003
C-reactive protein levels in obstructive sleep apnea syndrome Source: Eur Respir J 2005; 26: Suppl. 49, 356s Year: 2005
Effect of 8 week CPAP therapy on insulin resistance, serum leptin and lipid concentrations among obstructive sleep apnea hypopnea syndrome (OSAS) patients Source: Eur Respir J 2004; 24: Suppl. 48, 330s Year: 2004
Plasma homocysteine (Hcy) levels in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2007 - Cardiovascular and respiratory control in obstructive sleep apnoea Year: 2007
Metabolic disturbances in patients with obstructive sleep apnoea syndrome Source: Eur Respir Rev 2007; 16: 196-202 Year: 2007